Dernière mise à jour : 02 septembre 2016
Détails
FichiersGeneric Name:
Enzalutamide
État du projet:
Terminé
Domaine thérapeutique:
Metastatic Castration Resistant Prostate Cancer
Fabricant:
Astellas Pharma Canada Inc.
Brand Name:
Xtandi
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0023-000
Strength:
40 mg tablet
Tumour Type:
Genitourinary
Indications:
Metastatic Castration Resistant Prostate Cancer
Funding Request:
For the treatment of patients with metastatic castration-resistant prostate cancer, who have previously received docetaxel therapy
Review Status:
Complete
Pre Noc Submission:
Yes
Date NOC Issued:
Sponsor:
Astellas Pharma Canada Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 02 septembre 2016